{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:25:12Z","timestamp":1783617912162,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"grant for Childhood Cancer Research from the Gold Ribbon Network 2020"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12185-024-03856-3","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:01:51Z","timestamp":1727690511000},"page":"725-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Silent inactivation of asparaginase in Japan: results of the prospective ALL-ASP19 trial"],"prefix":"10.1007","volume":"120","author":[{"given":"Hidemi","family":"Shimonodan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyoshi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Keino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reo","family":"Tanoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-1088","authenticated-orcid":false,"given":"Souichi","family":"Suenobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"3856_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146\u201362.","journal-title":"Lancet"},{"key":"3856_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2015.137380","volume":"101","author":"IM van der Sluis","year":"2016","unstructured":"van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, Escherich G, Goulden N, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101:279\u201385.","journal-title":"Haematologica"},{"key":"3856_CR3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"LM Vrooman","year":"2013","unstructured":"Vrooman LM, Stevenson KE, Supko JG, O\u2019Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2013Dana-Farber Cancer Institute ALL Consortium Protocol 00\u201301. J Clin Oncol. 2013;31:1202\u201310.","journal-title":"J Clin Oncol"},{"key":"3856_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jjco\/hyy071","volume":"48","author":"K Koh","year":"2018","unstructured":"Koh K, Kato M, Saito AM, Kada A, Kawasaki H, Okamoto Y, et al. Phase II\/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan. Jpn J Clin Oncol. 2018;48:684\u201391.","journal-title":"Jpn J Clin Oncol"},{"key":"3856_CR5","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2352-3026(23)00072-8","volume":"10","author":"A Sato","year":"2023","unstructured":"Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, et al. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. Lancet Haematol. 2023;10:e419\u201332.","journal-title":"Lancet Haematol"},{"key":"3856_CR6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","volume":"11","author":"BL Asselin","year":"1993","unstructured":"Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780\u20136.","journal-title":"J Clin Oncol"},{"key":"3856_CR7","first-page":"478","volume":"6","author":"CA Fernandez","year":"2013","unstructured":"Fernandez CA, Cai X, Elozory A, Liu C, Panetta JC, Jeha S, et al. High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med. 2013;6:478\u201387.","journal-title":"Int J Clin Exp Med"},{"key":"3856_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0022-1759(00)00182-4","volume":"239","author":"B Wang","year":"2000","unstructured":"Wang B, Hak LJ, Relling MV, Pui CH, Woo MH, Storm MC. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia. J Immunol Methods. 2000;239:75\u201383.","journal-title":"J Immunol Methods"},{"key":"3856_CR9","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","volume":"18","author":"MH Woo","year":"2000","unstructured":"Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18:1525\u201332.","journal-title":"J Clin Oncol"},{"key":"3856_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaci.2004.12.1131","volume":"115","author":"EA Erwin","year":"2005","unstructured":"Erwin EA, Custis NJ, Satinover SM, Perzanowski MS, Woodfolk JA, Crane J, et al. Quantitative measurement of IgE antibodies to purified allergens using streptavidin linked to a high-capacity solid phase. J Allergy Clin Immunol. 2005;115:1029\u201335.","journal-title":"J Allergy Clin Immunol"},{"key":"3856_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3856_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjh.18745","volume":"201","author":"H Ishida","year":"2023","unstructured":"Ishida H, Imamura T, Tatebe Y, Ishihara T, Sakaguchi K, Suenobu S, et al. Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan association of childhood Leukaemia study ALL-02 protocol. Br J Haematol. 2023;201:1200\u20138.","journal-title":"Br J Haematol"},{"key":"3856_CR13","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1200\/JCO.19.03024","volume":"38","author":"S Gupta","year":"2020","unstructured":"Gupta S, Wang C, Raetz EA, Schore R, Salzer WL, Larsen EC, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children\u2019s oncology group. J Clin Oncol. 2020;38:1897\u2013905.","journal-title":"J Clin Oncol"},{"key":"3856_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","volume":"26","author":"EH Panosyan","year":"2004","unstructured":"Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children\u2019s cancer group study CCG-1961. J Pediatr Hematol Oncol. 2004;26:217\u201326.","journal-title":"J Pediatr Hematol Oncol"},{"key":"3856_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1046\/j.1365-2141.2001.03009.x","volume":"114","author":"HJ Muller","year":"2001","unstructured":"Muller HJ, Beier R, Loning L, Blutters-Sawatzki R, Dorffel W, Maass E, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001;114:794\u20139.","journal-title":"Br J Haematol"},{"key":"3856_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","volume":"96","author":"E Ahlke","year":"1997","unstructured":"Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, Werber G, Borste H, Wurthwein G, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997;96:675\u201381.","journal-title":"Br J Haematol"},{"key":"3856_CR17","doi-asserted-by":"crossref","first-page":"JCO2301797","DOI":"10.1200\/JCO.23.01797","volume":"42","author":"IM van der Sluis","year":"2024","unstructured":"van der Sluis IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, Bierings M, van den Bos C, et al. Continuous PEGasparaginase dosing reduces hypersensitivity reactions in pediatric ALL: a dutch childhood oncology group ALL11 Randomized Trial. J Clin Oncol. 2024;42:JCO2301797.","journal-title":"J Clin Oncol"},{"key":"3856_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.19.02292","volume":"38","author":"RQH Kloos","year":"2020","unstructured":"Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic Leukemia. J Clin Oncol. 2020;38:715\u201324.","journal-title":"J Clin Oncol"},{"key":"3856_CR19","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1080\/10428194.2017.1386305","volume":"59","author":"W Salzer","year":"2018","unstructured":"Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59:1797\u2013806.","journal-title":"Leuk Lymphoma"},{"key":"3856_CR20","first-page":"4554","volume":"41","author":"R Riccardi","year":"1981","unstructured":"Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 1981;41:4554\u20138.","journal-title":"Cancer Res"},{"key":"3856_CR21","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood. 2002;99:1986\u201394.","journal-title":"Blood"},{"key":"3856_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","volume":"32A","author":"J Boos","year":"1996","unstructured":"Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A:1544\u201350.","journal-title":"Eur J Cancer"},{"key":"3856_CR23","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1097\/MPH.0b013e3182986559","volume":"36","author":"Y Kawahara","year":"2014","unstructured":"Kawahara Y, Morimoto A, Hayase T, Kashii Y, Fukuda T, Momoi MY. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses. J Pediatr Hematol Oncol. 2014;36:e91\u20133.","journal-title":"J Pediatr Hematol Oncol"},{"key":"3856_CR24","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","volume":"97","author":"LB Silverman","year":"2001","unstructured":"Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91\u201301. Blood. 2001;97:1211\u20138.","journal-title":"Blood"},{"key":"3856_CR25","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/sj.leu.2401162","volume":"12","author":"MH Woo","year":"1998","unstructured":"Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:1527\u201333.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03856-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03856-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03856-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T14:05:43Z","timestamp":1732543543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03856-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3856"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03856-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}